Evommune, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-06
- Evommune, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $4.25M.
- Evommune, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$10.55M.
- Evommune, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $29.02M.
- Evommune, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$12.77M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.76M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $4.25M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $29.02M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $11.77M 10-Q · filed 2025-12-11 | |||
| 2025-06-30 | $45.58M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | -$10.55M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$12.77M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | -$10.88M 10-Q · filed 2025-12-11 |